title: Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study.
abstract: The number of circulating CD4+ T cells constitutively expressing CD25 (T regulatory, Treg) and natural killer T (NK T) cells, the two major lymphocyte populations that help to maintain immune homeostasis, was studied in 22 unselected myasthenia gravis (MG) patients, 16 healthy subjects and 24 patients with cancer, the latter as a disease model of a relative immune suppression status. Treg cells were assessed according to their intermediate or high level of expression of CD25, i.e., CD25int and CD25bright, and to the expression of HLA-DR, CD62L, CD45RO and CD152. There were no differences in the number of NK T cells and CD4+CD25bright cells among the three series of individuals. MG patients and healthy subjects had also similar numbers of CD4+CD25int cells. However, the whole CD4+ cell compartment in MG patients was in an activated status, as indicated by the higher level of expression of CD152. By contrast, and consistent with a relative immune suppression status, cancer patients had higher numbers of CD4+CD25int cells and larger proportions of HLA-DR expressing CD4+CD25int and CD4+CD25bright cells. Immunomagnetically purified CD4+CD25+ cells from MG, healthy subjects and cancer patients were anergic and suppressed the proliferative response of other T cells.
authors.affiliation: Department of Oncological Gynecology, Catholic University, Roma, Italy. cytogyn@rm.unicatt.it
authors.forename: A
authors.initials: A
authors.lastname: Battaglia
authors.forename: C
authors.initials: C
authors.lastname: Di Schino
authors.forename: A
authors.initials: A
authors.lastname: Fattorossi
authors.forename: G
authors.initials: G
authors.lastname: Scambia
authors.forename: A
authors.initials: A
authors.lastname: Evoli
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000378:metabolism; D060908:CTLA-4 Antigen; D002648:Child; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007107:Immune System; D018189:Immunomagnetic Separation; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000378:metabolism; D019041:L-Selectin / Q000096:biosynthesis; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000097:blood* / Q000473:pathology*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*; D013601:T-Lymphocytes / Q000166:cytology* / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D015375:Receptors, Interleukin-2; D019041:L-Selectin; D017493:Leukocyte Common Antigens